Title
Histamine resets the circadian clock in the suprachiasmatic nucleus through the H1R-CaV1.3-RyR pathway in the mouse

Permalink
https://escholarship.org/uc/item/4r6079tq

Journal
European Journal of Neuroscience, 42(7)

ISSN
0953-816X

Authors
Kim, Yoon Sik
Kim, Young-Beom
Kim, Woong Bin
et al.

Publication Date
2015-10-01

DOI
10.1111/ejn.13030

Copyright Information
This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at https://creativecommons.org/licenses/by-nc/4.0/

Peer reviewed
Histamine resets the circadian clock in the suprachiasmatic nucleus through the H1R-CaV1.3-RyR pathway in the mouse

Yoon Sik Kim,† Young-Beom Kim,† Woong Bin Kim,† Bo-Eun Yoon,‡,§ Feng-Yan Shen,† Seung Won Lee,† Tuck-Wah Soong,*, Hee-Chul Han,† Christopher S. Colwell,∥ C. Justin Lee‡ and Yang In Kim†

†Department of Physiology and Neuroscience Research Institute, Korea University College of Medicine, Seoul 136-705, Korea
‡Center for Neural Science and Center for Functional Connectomics, Korea Institute of Science and Technology, Seoul 136-791, Korea
§Department of Nanobiomedical Science, Dankook University, Chungnam, Korea
∥Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore Bik MD9, Singapore, Singapore

Keywords: brain slice, calcium, dantrolene, electrophysiology, nimodipine

Received 27 January 2015, revised 20 July 2015, accepted 23 July 2015

Abstract
Histamine, a neurotransmitter/neuromodulator implicated in the control of arousal state, exerts a potent phase-shifting effect on the circadian clock in the rodent suprachiasmatic nucleus (SCN). In this study, the mechanisms by which histamine resets the circadian clock in the mouse SCN were investigated. As a first step, Ca²⁺-imaging techniques were used to demonstrate that histamine increases intracellular Ca²⁺ concentration ([Ca²⁺]i) in acutely dissociated SCN neurons and that this increase is blocked by the H1 histamine receptor (H1R) antagonist pyrilamine, the removal of extracellular Ca²⁺ and the L-type Ca²⁺ channel blocker nimodipine. The histamine-induced Ca²⁺ transient is reduced, but not blocked, by application of the ryanodine receptor (RyR) blocker dantrolene. Immunohistochemical techniques indicated that CaV1.3 L-type Ca²⁺ channels are expressed mainly in the somata of SCN cells along with the H1R, whereas CaV1.2 channels are located primarily in the processes. Finally, extracellular single-unit recordings demonstrated that the histamine-elicited phase delay of the circadian neural activity rhythm recorded from SCN slices is blocked by pyrilamine, nimodipine and the knockout of CaV1.3 channel. Again, application of dantrolene reduced but did not block the histamine-induced phase delays. Collectively, these results indicate that, to reset the circadian clock, histamine increases [Ca²⁺]i in SCN neurons by activating CaV1.3 channels through H1R, and secondarily by causing Ca²⁺-induced Ca²⁺ release from RyR-mediated internal stores.

Introduction
The master circadian clock of the mammal located in the hypothalamic suprachiasmatic nucleus (SCN; Antle & Silver, 2005; Herzog, 2007; Golombek & Rosenstein, 2010; Welsh et al., 2010), which drives the diverse diurnal rhythms of physiological and behavioral variables, is regulated by various neural factors (Gillette & Mitchell, 2002; Reghunandanan & Reghunandanan, 2006; Challet, 2007; Golombek & Rosenstein, 2010). One example is histamine, a neurotransmitter/neuromodulator that is produced by neurons in the tuberomammillary nucleus (TMN; Watanabe et al., 1984) and plays a key role in the regulation of brain arousal (Haas & Panula, 2003). Studies have shown that the SCN is innervated by histaminergic fibers from the TMN (Watanabe et al., 1984) and that some SCN neurons in the mouse and rat contain histamine, presumably because they take up histamine released from histaminergic nerve terminals (Michelsen et al., 2005). The application of histamine onto SCN neurons in rodent hypothalamic slice preparations alters the firing rates of these cells (Liou et al., 1983; Stehle, 1991; Scott et al., 1998), while bath application of histamine phase-shifts the circadian rhythms in neural activity recorded in hamster and mouse SCN slices (Cote & Harrington, 1993; Meyer et al., 1998; Biello, 2009). In vivo, the intracerebroventricular injection of histamine in the rat phase-shifts the circadian activity rhythms (Itowi et al., 1990) and reduces the time required to entrain activity rhythms to an abruptly advanced light–dark cycle (Itowi et al., 1991). The inhibition of histamine synthesis by N-fluoromethylhistidine or knockout (KO) of histidine decarboxylase gene disrupts the circadian activity rhythm in rats (Itowi et al., 1990), attenuates the light-induced phase shifts of circadian activity rhythms in hamsters (Eaton et al., 1995) and lowers the levels of wheel-running and spontaneous locomotor activities in mice in both light–dark and dark–dark conditions (Abe...
et al., 2004). Finally, H1 histamine receptor (H1R) KO mice exhibit disrupted diurnal feeding rhythm (Yoshimatsu, 2008). Collectively, these data indicate that histamine is a potent regulator of the circadian system in mammals, and raise questions about the underlying mechanisms.

In the present study, it was sought to determine the molecular mechanism by which histamine resets the circadian clock in the mouse SCN. CaV2+−imaging techniques were first used to measure the CaV2+ transients evoked by application of histamine to isolated SCN neurons and to identify the signaling pathway by which histamine regulates this key intracellular signaling molecule, as circadian clock resetting requires an intracellular CaV2+ concentration ([Ca2+][i]) increase in SCN neurons (Ding et al., 1994, 1998; Hamada et al., 1999; Kim et al., 2005). Next, immunohistochemistry (IHC) was used to examine the co-localization of H1R with CaV1.3 L-type voltage-gated CaV2+ channels (VGCCs). Finally, extracellular single-unit recordings were used to determine the signaling pathway by which histamine phase-shifts the circadian rhythm in neural activity recorded from the SCN.

Materials and methods

Study approval

The experimental procedures described below were approved by the Korea University College of Medicine Animal Research Policies Committee and Korea Institute of Science and Technology, while conforming to National Institutes of Health guidelines.

Animals and housing

Male C57BL/6 mice (B6 mice, 3–6 weeks old) and CaV1.3 KO mice (3–6 weeks old) with the genetic background of C57BL/6 were used for the current study. The double-KO mouse CaV1.3/ CaV3.1 animal was received from Dr. Matteo Mangoni at CNRS, UMR-5203, Institut de Génomique Fonctionnelle, D’partement de Physiologie, LabEx ICST, Montpellier, F-34094, France in August 2008. The targeting of CaV1.3 allele was achieved by thymidine kinase gene, a 1.4-kb genomic fragment 5′ to exon 2, the neomycin resistance (neo) gene driven by the pgk promoter inserted in the reverse direction into the ClaI site of exon 2, a 5-kb genomic fragment 3′ to exon 2, and the plasmid pKO V910 (Lexicon Genetics). After receiving this mouse line, each allele was isolated by crossing with wild-type mice in several generations to obtain pure CaV1.3 KO line. Animals were housed in group cages (four-six/cage) in a temperature-controlled room (22–24 °C) and adapted to a 12-h light-dark cycle for at least 1 week before being used for experiments. Zeitgeber time (ZT) 0:00 h was designated as the time of lights-on and ZT 12:00 h as the time of lights-off in the colony.

Brain slice preparation

All brain slices were prepared between ZT 10:00 h and 12:00 h. Animals were anesthetized with urethane (1.25 g/kg, i.p.), and the brain was quickly excised from the skull and submerged in 95% CO2/5% O2 saturated ice-cold artificial cerebrospinal fluid (ACSF), composed of (in mM): NaCl, 124; MgSO4, 1.3; KCl, 3; NaH2PO4, 1.25; NaHCO3, 26; CaCl2, 2.4; glucose, 10. After being chilled in ice-cold ACSF for 1–2 min, the brain was trimmed to a tissue block containing the hypothalamus. Using a vibrisslicer (World Precision Instruments or Leica VT100S), coronal slices (300–400 μm thickness) containing the SCN were cut from the tissue block in ice-cold ACSF. The slices were kept at room temperature (R/T: 22–24 °C, 30–60 min) in aerated (95% O2/5% CO2) ACSF before being transferred to a gas interface-type electrophysiological recording chamber that was continuously superfused with warm (35 °C) 95% O2/5% CO2-saturated ACSF.

SCN cell dissociation

Hypothalamic slices containing the SCN (300–350 μm thickness; coronal orientation) were prepared between ZT 10:00 h and 12:00 h from B6 mice as above. After being incubated in aerated (95% O2/ 5% CO2) ACSF at R/T (30–60 min), the slices were transferred to a HEPES-buffered high-sucrose solution (‘high-sucrose’ solution) [composed of (in mM): Na2SO4, 30; K2SO4, 2; sucrose, 185; glucose, 10; HEPES, 10; CaCl2, 0.5; MgCl2, 6; pH 7.4] containing 2 mg/mL protease XXIII (Sigma-Aldrich) and incubated for 15 min at 34 °C. After this enzyme treatment, the slices were rinsed with the high-sucrose solution at R/T and incubated again in the high-sucrose solution containing 1 mg/mL trypsin inhibitor and 1 mg/mL bovine serum albumin (Sigma-Aldrich) for 15 min at R/T. Subsequently, the slices were rinsed with the high-sucrose solution, and the SCN was ‘punched out’ with blunt 21-G needle for mechanical dissociation of cells. The cells dissociated with the use of fire-polished glass pipettes were plated on poly-β-lysine (Sigma-Aldrich)-coated glass coverslips. The cells were allowed to settle down on the coverslips for ~30 min at R/T and then were washed with the HEPES-buffered saline, before fura-2 loading (below).

CaV2+ imaging

Dissociated SCN cells on the coverslips were loaded with fura-2 AM (Invitrogen) for CaV2+ imaging. For this, the coverslips were incubated for 30 min in fura-2 AM (5 μM)-containing HEPES-buffered saline [composed of (in mM): NaCl, 150; KCl, 5; CaCl2, 2; MgCl2, 1; HEPES, 10; glucose, 10; pH 7.4] at R/T, and then rinsed with HEPES-buffered saline before being transferred to the imaging chamber (RC-25; Warner Instrument, Hamden, CT, USA) that was superfused continuously (1–1.5 mL/min) with Mg2+-free HEPES-buffered saline (22–24 °C). CaV2+ responses to a mixture of 100 μM glycine and 100 μM N-methyl-D-aspartate (NMDA) were used as a positive control in CaV2+ imaging tests; glycine acts as a co-agonist of NMDA receptors (Johnson & Asher, 1987). Background-subtracted intensity images at two excitation wavelengths (340 and 380 nm) were acquired using an EMCCD camera (Andor Technology, UK) attached to an inverted microscope (IX71; Olympus, Tokyo, Japan) and Axon Imaging Work Bench 5.1 image processing program (Indec Systems, CA, USA). [Ca2+][i] was expressed as the ratio of the fura-2 emission fluorescence intensities of 510 nm, excited at 340 and 380 nm. All the CaV2+−imaging experiments were performed between ZT 13:00 h and ZT 18:00 h.

IHC

B6 mice were anesthetized with avertin (2,2,2-trichloroethanol; 0.4 g/kg i.p.) or urethane (1.25 g/kg, i.p.) and perfused with ice-cold 0.9% saline, and then with 4% paraformaldehyde (prepared in 0.1 m phosphate buffer). Brains were excised from the skull and post-fixed in ice-cold 4% paraformaldehyde overnight. Then, the brains were cryoprotected in ice-cold 4% paraformaldehyde for 14 days and then with 30% sucrose-containing 0.1 m phosphate-buffered saline (PBS) for 24 h and frozen in powdered dry ice. Coronal sections (30 μm) containing the SCN were cut from the frozen brain tissue with a cryostat and transferred to...
0.1 mM PBS for washing. Subsequently, they were transferred to a blocking solution, the 0.1 mM PBS containing 0.3% Triton-X 100 and 4% normal donkey serum. After 1 h in the blocking solution, the tissue sections were incubated overnight at 4 °C with a mixture of primary antibodies: goat anti-H1R (1 : 50, sc-19770; Santa-Cruz) antibody plus rabbit anti-Ca_v1.2 (1 : 200, ACC-003; Alomone LAB, Jerusalem, Israel) antibody or goat anti-H1R antibody (1 : 50; Santa-Cruz) plus rabbit anti-Ca_v1.3 antibody (1 : 50; Shen et al., 2006). The sections for double-ICHC were washed with 0.1 mM PBS and incubated with Alexa Fluor-488 and Alexa Fluor-555 (each 1 : 200; Invitrogen)-conjugated secondary antibodies diluted in blocking solution for 2 h at R/T. After being washed in 0.1 mM PBS, the sections were stained with 4′,6-diamidino-2-phenylindole (DAPI), a fluorescent stain that binds strongly to DNA and thus delineates cellular nuclei. The floating sections were transferred to Superfrost Plus slides (Fisher) and dried. All slides were cover-slipped in fluorescent mounting medium (Dako, Glostrup, Denmark) and examined with confocal microscopy. Confocal microscope images were captured with a Fluoview-1000 microscope (Olympus) using standard excitation and emission filters for visualizing Alexa Fluor-488 and Alexa Fluor-555. For images, micrographs were made using 40–100× objective lenses in the Fluoview confocal microscope. For image analysis, FV10-ASW program (Olympus) and Image-J (NIH, MD, USA) were used.

**Experimental treatment and extracellular single-unit recording**

On the first day *in vitro*, the slice was superfused in the recording chamber with a solution containing histamine, 2-pyridylethylamine (H1R agonist) or amphetamine [H2 histamine receptor (H2R) agonist] in some experiments, histamine was superfused together with pyrilamine (H1R blocker), nimodipine (L-type VGCC blocker), dan-trolene [ryanodine receptor (RyR) blocker] or a cocktail of di,2-amino-5-phosphonopentanoic acid (AP5; NMDA receptor antagonist) and 6,7-dimotiquinoxaline-2,3-dione (DNQX; non-NMDA receptor antagonist). Control slices were not treated with any of the drugs above. The application of histamine or H1R/H2R agonist began at ZT 14:00 h and lasted for 30 min. The application of blockers started at ZT 13:50 h and lasted for 50 min.

On the next day (i.e. second day *in vitro*), extracellular single-unit recordings were obtained from the SCN between ZT 1:00 h and ZT 16:00 h has described previously (Kim et al., 2005). Micropipettes (4–6 MΩ) pulled from borosilicate glass capillary and filled with ACSF were used as recording electrodes. Unit recordings were conducted without restricting the electrode tip to any particular region of the SCN. Usually 6–15 units were sampled every hour, each unit being recorded for a 1-min period. The voltage signals from recording electrodes were fed serially into an Axoclamp-2B amplifier (Molecular Devices, CA, USA), and a differential amplifier (model AM 502; Tektronix) for amplification, AC coupling and band-pass filtering (200 Hz–1 kHz). The processed signals were digitized and sampled at 50-μs intervals (Digidata1320A, Axoscope 8.1; Molecular Devices). The criteria used to identify single units were consistent waveform and spike amplitude. To detect the time-of-peak of circadian firing activity rhythm of SCN neurons, which is a reliable marker of the phase of circadian pacemaker (Chen et al., 1999), the mean firing rates of single units sampled for sequential 2-h periods with 1-h lags were plotted against ZT: i.e. the mean firing rate of units recorded from ZT 0:00 h to 2:00 h at ZT 1:00 h were plotted, the mean firing rate of units encountered from ZT 1:00 h to 3:00 h at ZT 2:00 h were plotted, etc. In order to quantify the phase shift induced by a drug treatment, the time-of-peak detected in the drug-treated slice was compared with the average time-of-peak of control slices. The difference was taken as the amount of drug-induced phase shift.

**Drugs**

All drugs and chemicals used in the current study were purchased from Sigma-Aldrich and Tocris Bioscience (Bristol, UK). The solutions of histamine, 2-pyridylethylamine, amphetamine, pyrilamine, AP5 and quinacrine were prepared by dissolving these drugs in ACSF or HEPES-buffered saline at appropriate concentrations. The solutions of DNQX, nimodipine, dantrolene, chelerythrine, bisindolylmaleimide-1 and BTP-2 were prepared by diluting their stock solution with ACSF or HEPES-buffered saline [stock solution solvent – dimethyl sulfoxide (DMSO) for DNQX, nimodipine and dantrolene; final concentration of DMSO = 0.003–0.01%]. These drug solutions were applied to SCN slices or dissociated SCN cells by gravity-fed bath-perfusion system or peristaltic pump. Drug solutions were kept in syringe reservoirs connected to a manifold with multiple inputs (Warner Instrument). The opening and closing of each reservoir was controlled by an electronically operated solenoid valve. The output of the manifold was connected to the recording chamber.

**Statistics**

Numerical data are expressed as the mean ± SEM. All statistical tests were conducted using SigmaStat 3.5 (Systat Software). Unpaired t-test was used for the comparison of two independent data sets with normal distribution. Paired samples with and without normal distribution were compared with paired t-test and Wilcoxon signed rank test, respectively. Kruskal–Wallis one-way analysis of variance (ANOVA) on ranks and pair-wise comparison with Newman–Keuls tests were performed to compare multiple data sets without normal distributions. A value of P < 0.05 was considered to be significant. For tests involving 1 degree of freedom, a non-directional test was conducted.

**Results**

**H1R mediates histamine-induced [Ca2+]i increase in SCN neurons**

First, it was examined whether histamine increased [Ca2+]i in acutely dissociated mouse SCN neurons (Fig. 1A) using Fura-2 as a Ca2+ indicator. Cells showing Ca2+ responses to NMDA were taken as neurons (Fig. 1B) because cultured mouse glia do not respond to NMDA with changes in [Ca2+]i (Y.S. Kim and C.J. Lee, unpublished data, 2015). The main reason the use of dissociated cells was chosen over brain slices for Ca2+ imaging was that the dissociated cell preparation allows to precisely predict the cellular mechanism in an isolated setting; in a brain slice experimental setting, various transmitters can be released from neighboring neurons or glial cells upon activation and give rise to secondary or indirect responses. Bath application of histamine (100 μM; 30 s) produced a reliable increase in [Ca2+]i in a subset of SCN neurons (323 out of 683 cells from 39 mice; Fig. 1B); the average peak amplitude of histamine-induced Ca2+ responses (expressed as the change in the ratio of emissions at 340 nm and 380 nm of light) was 0.36 ± 0.02 (n = 323). In the remaining neurons, histamine produced either a decrease (n = 9 cells, −0.48 ± 0.09) or no change in [Ca2+]i (n = 351 cells).
H1R and H2R mediate the excitatory actions of histamine in the brain (Haas & Panula, 2003). Thus, it was tested whether H1R or H2R mediates the histamine-induced Ca2+ increase in SCN neurons using selective histamine receptor agonists and antagonists. The H1R agonist 2-pyridylethylamine (100 μM; 30 s) evoked a large increase in [Ca2+]i, whereas the H2R agonist amthamine (20 μM; 30 s) showed only a marginal effect [peak Ca2+ responses, H1R agonist: 0.7 ± 0.3, n = 15 neurons (from three mice); H2R agonist: 0.1 ± 0.0, n = 20 neurons (from three mice); unpaired t-test, t13 = 5.09, P < 0.001; Fig. 1C]. In addition, the H1R antagonist pyrilamine (10 μM) mostly blocked the histamine-elicited Ca2+ response [% block of Ca2+ peak amplitude: 86.6 ± 5.5%, n = 13 neurons (from three mice); paired t-test, t12 = 5.32, P < 0.001; Fig. 1D], indicating that H1R mediates the histamine-evoked Ca2+ increase in SCN neurons. Pyrilamine and all other blockers except the protein kinase C (PKC) inhibitor chelerythrine, which were tested for their possible antagonistic effects on histamine-activated Ca2+ responses (see below), did not alter the baseline Ca2+ level (data not shown). Also, the drug vehicle (i.e. 0.01% DMSO) had no significant effect on the baseline [Ca2+]i (data not shown).

To investigate the possible mechanisms underlying the histamine-induced [Ca2+]i increase in SCN neurons, first it was determined whether histamine can evoke a response in a Ca2+-free bath solution containing 100 μM EGTA. EGTA was included to remove possible remaining free Ca2+ in nominally Ca2+-free bath solution. After switching to the Ca2+-free medium, the baseline ratio (340/380) gradually decreased by 0.3–0.7 until a new baseline ratio was established within 5–10 min. In this condition, histamine application failed to increase [Ca2+]i (Fig. 2A), indicating that the histamine-induced increases in [Ca2+]i in SCN neurons crucially depend on the influx of Ca2+. Next, because L-type VGCCs are a major route for Ca2+ influx and are highly expressed in the SCN (Nahm et al., 2005), the effect of the L-type VGCC blocker nimodipine on histamine-induced Ca2+ release was examined. Nimodipine (2 μM) blocked the Ca2+ response (t18 = 6.11, P ≤ 0.001; Fig. 2B). These results indicate that L-type VGCC is responsible for the Ca2+ entry.
Then, the possible contribution of Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+} release from internal stores (Chavis et al., 1996; Dulhunty et al., 2002) with the use of the RyR blocker dantrolene was examined. The application of this agent (10 μM) reduced the histamine-induced Ca\textsuperscript{2+} response by 50.3 ± 6.1% (0.19 ± 0.03 to 0.09 ± 0.02, t\textsubscript{32} = 7.20, P ≤ 0.001, n = 33 from three mice; paired t-test; Fig. 2C). In contrast, the histamine-induced Ca\textsuperscript{2+} responses were not impacted by the application of the transient receptor potential cation channel (TRPC) blocker BTP-2 (3 μM; He et al., 2005), the PKC inhibitors (chelerythrine, 2 μM; bisindolylmaleimide-1, 1 μM), or the phospholipase A2 (PLA2) inhibitor quinacrine (10 μM; Kim et al., 2004; Shim et al., 2007; Fig. 3). Collectively, these results indicate that histamine-induced [Ca\textsuperscript{2+}]\textsubscript{i} increases in mouse SCN neurons are largely mediated by L-type VGCCs with some contribution from Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+} release from internal stores, whereas downstream effectors of phospholipase C (PLC) and PLA2 are not involved.

**Ca\textsubscript{V}1.3 mediates the actions of histamine**

While there are four subtypes of L-type VGCCs (Ca\textsubscript{V}1.1~1.4), only Cav1.2 and Cav1.3 subtypes are expressed in the CNS (Moosmang et al., 2005; Calin-Jageman & Lee, 2008). To see which subtype is expressed in mouse SCN cells, double-IHC with antibodies against H1R and Ca\textsubscript{V}1.2 or Ca\textsubscript{V}1.3 was performed. The control staining conditions for Ca\textsubscript{V}1.2, Ca\textsubscript{V}1.3 and H1R include the absence of staining for Ca\textsubscript{V}1.2 in Ca\textsubscript{V}1.2 conditional KO mouse, absence of staining for Ca\textsubscript{V}1.3 in Ca\textsubscript{V}1.3 KO mouse, and absence of staining for H1R with the control peptide-preabsorbed antibody, respectively (Fig. 4A). It was found that Ca\textsubscript{V}1.3 and H1R are mainly expressed in the somata of SCN cells, whereas Ca\textsubscript{V}1.2 is located primarily in the processes (Fig. 4B). More importantly, almost all of H1R-positive somata were also positive for Ca\textsubscript{V}1.3, but rarely for Ca\textsubscript{V}1.2 (% co-localization, H1R and Ca\textsubscript{V}1.3: 98.8 ± 0.4%, n = 3 sections from...
three mice; H1R and CaV1.2: 5.5 ± 1.5%, n = 6 sections from six mice; unpaired t-test, \( t_{7} = -22.68, P < 0.001 \).

Furthermore, the percentage of H1R-positive cells in the SCN was 47.4% (n = 9 slices) and this was very similar to the percentage of cells showing a histamine-induced increase in \([\text{Ca}^{2+}]_{i}\) (47%). Previous work has shown that CaV1.2 and CaV1.3 show differential sensitivity to nimodipine – the IC50 values of nimodipine for CaV1.2 and CaV1.3 were 139 nM and 2.7 μM, respectively (Xu & Lipscombe, 2001). To identify the L-type VGCC subtype that is responsible for the histamine-induced \([\text{Ca}^{2+}]_{i}\) entry, this differential sensitivity was utilized. It was assumed that 0.3 μM nimodipine would selectively block CaV1.2, while nimodipine at 6 μM would block both CaV1.2 and CaV1.3. It was found that 0.3 μM nimodipine only modestly reduced the histamine-evoked increase in \([\text{Ca}^{2+}]_{i}\), (14.9 ± 7.1% block, n = 8 neurons from two mice), whereas 6 μM nimodipine blocked almost completely the histamine-induced \([\text{Ca}^{2+}]_{i}\) response (88.0 ± 8.5% block, n = 5 neurons from two mice). The effects of 0.3 and 6 μM nimodipine were significantly different.

Fig. 3. Phospholipase C (PLC) and phospholipase A2 (PLA2) pathways do not mediate histamine-induced \([\text{Ca}^{2+}]_{i}\) responses in suprachiasmatic nucleus (SCN) neurons. Effects of protein kinase C (PKC) inhibitors [chelerythrine, n = 37; bisindolylmaleimide-1, n = 39; (A)], PLA2 inhibitor [quinacrine, n = 26; (B)] and transient receptor potential cation channel (TRPC) blocker [BTP-2, n = 26; (C)] on histamine-elicited \([\text{Ca}^{2+}]_{i}\) responses in SCN neurons. The effect of bisindolylmaleimide-1 was examined in addition to the effect of chelerythrine, because the latter induced the upward sloping of the baseline ratio that may indicate dying cell. ns, statistically not significant, paired t-test. The bar charts in (A–C) indicate the mean (±SEM) values.
Therefore, the expression data as well as nimodipine sensitivity indicate that CaV1.3 L-type VGCC mediates the histamine-induced Ca2+ influx in mouse SCN neurons.

**Histamine resets the circadian clock through the H1R-CaV1.3-RyR pathway**

In the final set of experiments, it was sought to determine if histamine causes phase shifts using the H1R-CaV1.3-RyR signaling pathway. Electrophysiological techniques were used to determine how the blockade or removal of H1R, CaV1.3 or RyR by selective pharmacological or genetic manipulations altered the histamine-induced phase delay of circadian neural activity rhythm recorded from the mouse SCN. In this brain slice preparation, spontaneous neural activity is rhythmic with a peak of electrical activity at midday or ZT 6.00 ± 0.26 h (n = 6; Fig. 5A and P). In those slices treated with histamine (100 μM, for 30 min at ZT 14 h), the peak was phase-delayed almost 6 h to ZT 11.50 ± 0.23 h (n = 6; Fig. 5B and P) by the next cycle. This phase-delaying effect of histamine was mimicked by the H1R agonist 2-pyridylethylamine (100 μM; Fig. 5C and P), but not the H2R agonist amthamine (20 μM;
neural activity (Aguilar-Roblero et al., 2007), intracellular calcium (Ikeda et al., 2003) and circadian behavior (Mercado et al., 2009).

\[ \text{CaV}_{1.3}, \text{ but not CaV}_{1.2}, \text{ mediates the histamine-induced Ca}^{2+}-\text{ influx} \]

The IHC results demonstrate that both CaV_{1.2} and CaV_{1.3} are present in mouse SCN cells. However, the results from the Ca^{2+}-imaging study suggest that CaV_{1.3} mediates most of the histamine-induced Ca^{2+} influx. This could be due to the fact that CaV_{1.3} is tightly coupled to H1R through certain signaling pathways(s), whereas CaV_{1.2} is not or is weakly coupled to this receptor. The current finding that CaV_{1.3}, but not CaV_{1.2}, is co-localized extensively with H1R in the somas of SCN cells is consistent with this hypothesis.

Histamine phase-delays the circadian clock through the H1R–CaV_{1.3}–RyR pathway

The results of the functional assay indicate that histamine activates the H1R–CaV_{1.3}–RyR pathway to phase-delay the circadian pacemaker. This conclusion is consistent with the finding of a previous study that the H1R antagonist mepyramine blocked the histamine (1 \mu M)-induced phase delays of circadian firing activity rhythms recorded in golden hamster SCN slices (Cote & Harrington, 1993). However, it does not agree with the report from the same laboratory that histamine-induced phase shifts were not blocked by mepyramine but were sensitive to the NMDA receptor antagonist AP5 (Meyer et al., 1998). In the current study, it was found that a cocktail of AP5 and DNQX (non-NMDA receptor antagonist) had no effect on the histamine (100 \mu M)-induced phase delay in the mouse SCN slice. Instead, the H1R antagonist pyrilamine (10 \mu M) was very effective in blocking the phase delay. It is unclear why histamine-induced phase shifts were not blocked by H1R antagonists but were sensitive to NMDA receptor antagonist in a previous study (Meyer et al., 1998). The use of a low concentration of mepyramine (100 nm) might be an explanation. Or, it may be related to the use of the hamster, a species in which the SCN is almost devoid of histaminergic fibers, histamine exerts only a weak phase-shifting effect on the free-running locomotor activity rhythm, and the modest effects of histamine on the firing rates of SCN neurons are blocked by neither H1R nor H2R antagonists (Scott et al., 1998).

At present, it is not known which signaling mechanism(s) couples H1R to CaV_{1.3}. The PLC or PL2A pathway, however, is unlikely to be upstream of CaV_{1.3} in the light of the results from the current Ca^{2+}-imaging study. CaV_{1.3} is a VGCC that is activated by membrane depolarization, and it has been reported that histamine induces membrane depolarization in other hypothalamic neurons (Li & Hatton, 1996; Smith & Armstrong, 1996; Zhou et al., 2007) and that H1R activation leads to membrane depolarization through the G_{q/11} protein-mediated blockade of leak channels (Li & Hatton, 1996; Jafri et al., 1997; Haas & Panula, 2003; Zhou et al., 2007). Thus, it

Discussion

Mechanism underlying the histamine-elicited Ca^{2+} rise in SCN neurons

It is well known that the H1R is coupled to the G_{q/11}–PLC pathway, which mediates most of the excitatory histaminergic actions in the brain. The activation of the G_{q/11}–PLC pathway leads to the formation of inositol 1,4,5-trisphosphate (IP_3), diacyl-glycerol (DAG) and PL2A (Haas & Panula, 2003; Haas et al., 2008). IP_3 can induce Ca^{2+} release from the intracellular stores by acting on IP_3 receptor, while DAG can cause Ca^{2+} influx by activating TRPC channels (Hofmann et al., 1999; Haas et al., 2008). Previous work has indicated that IP_3-mediated Ca^{2+} release from SCN neurons is critical for the glutamate-induced phase delay of the circadian neural activity rhythm in the SCN (Hamada et al., 1999). The current results do not support the idea that histamine leads to IP_3-mediated intracellular Ca^{2+} release in SCN neurons mainly because histamine-induced [Ca^{2+}]_i rise was eliminated by the removal of external Ca^{2+} or by the L-type Ca^{2+} channel blocker nimodipine. In addition, the histamine-induced [Ca^{2+}]_i rise persisted in the presence of the TRPC channel blocker BTP-2, PKC inhibitors (chelerythrine and bisindolylmaleimide-1) or the PL2A inhibitor quinacrine. These results indicate that the PLC or PL2A signaling pathways do not contribute to the histamine-induced [Ca^{2+}]_i increase in mouse SCN neurons. Instead, it was found that histamine increases [Ca^{2+}]_i, by activating L-type VGCCs through H1R, and secondarily by causing Ca^{2+}-injected Ca^{2+} release from RyR-mediated internal stores. Previous work has provided evidence that RyR expression (Pfeffer et al., 2009) and binding (Diaz-Munoz et al., 1999) are under circadian clock control. Furthermore, RyRs have been implicated to play a crucial role in the light-induced phase delay of the circadian clock (Ding et al., 1998), and are known to be potent regulators of SCN
is possible that the membrane depolarization arising from leak channel blockade by G_{av1} is responsible for the activation of Cav1.3 in SCN neurons that follows the binding of histamine to H1R.

Cav1.3 is activated not only by membrane depolarization, but also by phosphorylation (Qu et al., 2005; Ramadan & Boutjdir, 2009). Previous work indicates that H1R is positively coupled to the cAMP signaling pathway through G_{av1} protein (Marley et al., 1991; Maruko et al., 2005), and it is well known that cAMP is a strong activator of protein kinase A (PKA). Thus, it is also conceivable that the G_{av1}-cAMP/PKA signaling pathway is intercalated between H1R and Cav1.3. Whether or not these are indeed the mechanisms linking H1R to Cav1.3 awaits future studies.

Functional significance

The circadian system controls the timing of arousal through the regulation of the electrical activity in a network of neurotransmitter systems including the histamine-expressing cell population in the TMN. Conceptually, blocking the actions of histamine will help induce or maintain sleep, while increasing histamine levels will enhance arousal. At this point, anti-histamines are commonly used as ‘over the counter’ sleeping aids, while H3 histamine receptor antagonists are in clinical trials as potential treatment for cognitive impairments associated with neurodegenerative disorders (Benarroch, 2010; Lin et al., 2011; NIH clinical trials database – https://clinicaltrials.gov). These possible clinical uses raise questions about how the circadian system is influenced by histamine as well as pointing out the need to understand the underlying mechanisms. In this study, a new signaling pathway is uncovered that underlies the histamatergic regulation of the circadian system.

Acknowledgements

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2011-0022529; Y.I.K.) and Korea University Grant (K1031781; Y.I.K.), and by KIST institutional project, Program No. 2E25210 (C.J.L.), and Brain Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, NRF-2012M3C7A1055412 (C.J.L.), and WCI Program of National Research Foundation (C.J.L.); Y.S.K., Y.-B.K., W.B.K., S.W.L. and Y.I.K. were supported by the Brain Korea 21 Project from 2009 to 2014. C.S.C. was supported by the O’Keefe Foundation. The authors declare that there is no conflict of interests.

Abbreviations

[Ca^{2+}]_i, intracellular Ca^{2+} concentration; ACSF, artificial cerebrospinal fluid; AP5, d,l-2-amino-5-phosphonopentanoic acid; B6 mouse, C57BL/6 mouse; DAG, diacylglycerol; DAPI, 4,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; DNQX, 6,7-dinitroquinoxaline-2,3-dione; HIR, H1 histamine receptor; H2R, H2 histamine receptor; iGluR, ionotropic glutamate receptor; iHC, immunohistochemistry; IP3, 1,4,5-trisphosphate; KO, knockout; NMDA, N-methyl-D-aspartate; PBS, phosphate-buffered saline; PKA, protein kinase A; PKC, protein kinase C; PLAA2, phospholipase A2; PLC, phospholipase C; R/T, room temperature; RsR, ryantodine receptor; SCN, suprachiasmatic nucleus; TMN, tuberomammillary nucleus; TRPC, transient receptor potential cation channel; VGCC, voltage-gated Ca^{2+} channels; ZT, Zeitgeber time.

Author contributions

Y.S.K., T.-W.S., H.C.H., C.J.L. and Y.I.K. conceived this project. Y.S.K., Y.-B.K., W.B.K., B.E.Y., F.-Y.S. and S.W.L. performed the experiments and analysed the results. Y.S.K., C.S.C., C.J.L. and Y.I.K. wrote the manuscript.

References

Abe, H., Honma, S., Ohtsu, H. & Honma, K. (2004) Circadian rhythms in behavior and clock gene expressions in the brain of mice lacking histidine decarboxylase. Brain Res. Mol. Brain Res., 124, 178–187.

Aguilar-Roblero, R., Mercado, C., Alamilla, J., Laville, A. & Diaz-Munoz, M. (2007) Ryamodine receptor Ca^{2+}-release channels are an output pathway for the circadian clock in the rat suprachiasmatic nuclei. Eur. J. Neurosci., 26, 575–582.

Antle, M.C. & Silver, R. (2005) Orchestrating time: arrangements of the brain circadian clock. Trends Neurosci., 28, 145–151.

Benarroch, E.E. (2010) Histamine in the CNS Multiple functions and potential neurologic implications. Neurology, 75, 1472–1479.

Biello, S.M. (2009) Circadian clock resetting in the mouse increases with age. Age, 31, 293–303.

Calin-Jageman, I. & Lee, A. (2008) Ca(v)1 L-type Ca^{2+} channel signaling complexes in neurons. J. Neurochem., 105, 573–583.

Challet, E. (2007) Minireview: entrainment of the suprachiasmatic clock by diurnal and nocturnal mammals. Endocrinology, 148, 5648–5655.

Chavis, P., Faghi, L., Lansman, J.B. & Bockaert, J. (1996) Functional coupling between ryamodine receptors and L-type calcium channels in neurons. Nature, 382, 719–722.

Chen, D., Buchanan, G.F., Ding, J.M., Hannibal, J. & Gillette, M.U. (1999) Pituitary adenyl cyclase-activating peptide: a pivotal modulator of gluta-

matergic regulation of the suprachiasmatic circadian clock. Proc. Natl. Acad. Sci. USA, 96, 13468–13473.

Cote, N.K. & Harrington, M.E. (1993) Histamine phase shifts the circadian clock in a manner similar to light. Brain Res., 613, 149–151.

Diaz-Munoz, M., Dent, M.A., Grandos-Fuentes, D., Hall, A.C., Hernandez-Cruz, A., Harrington, M.E. & Aguilar-Roblero, R. (1999) Circadian modula-

tion of the ryantodine receptor type 2 in the SCN of rodents. NeuroRe-

port, 10, 481–486.

Ding, J.M., Chen, D., Weber, E.T., Faiman, L.E., Rea, M.A. & Gillette, M.U. (1994) Resetting the biological clock: mediation of nocturnal circa-

dian shifts by glutamate and NO. Science, 266, 1713–1717.

Ding, J.M., Buchanan, G.F., Tischkau, S.A., Chen, D., Kuriashkina, L., Fai-

mante, M., Kompehr, P.S., Campbell, K.P. & Gillette, M.U. (1998) A neuronal ryantodine receptor mediates light-induced phase delays of the circadian clock. Nature, 394, 381–384.

Dunbabin, A.F., Haarrmann, C.S., Green, D., Laver, D.R., Board, P.G. & Casar-

otto, M.G. (2002) Interactions between dihydropyridine receptors and ryant-

odine receptors in striated muscle. Prog. Biophys. Mol. Bio., 79, 45–75.

Eaton, S.J., Cote, N.K. & Harrington, M.E. (1995) Histamine synthesis inhi-

bition reduces light-induced phase shifts of circadian rhythms. Brain Res., 655, 227–230.

Gillette, M.U. & Mitchell, J.W. (2002) Signaling in the suprachiasmatic nucleus: selectively responsive and integrative. Cell Tissue Res., 309, 99–107.

Golombek, D.A. & Rosenstein, R.E. (2010) Physiology of circadian entrain-

ment. Physiol. Rev., 90, 1063–1102.

Haas, H. & Panula, P. (2005) The role of histamine and the tuberomammillary nucleus in the nervous system. Nat. Rev. Neurosci., 6, 121–130.

Haas, H.L., Sergeeva, O.A. & Selbach, O. (2008) Histamine in the nervous system. Physiol. Rev., 88, 1183–1241.

Hamada, T., Liou, S.Y., Fukushima, T., Maruyama, T., Watanabe, S., Mikoshibala, K. & Ishida, N. (1999) The role of inositol trisphosphate-in-

duced Ca^{2+} release from IP3-receptor in the rat suprachiasmatic nucleus on circadian entrainment mechanism. Neurosci. Lett., 263, 125–128.

He, L.P., Hewavitharana, T., Soboloff, J., Spassova, M.A. & Gill, D.L. (2005) A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J. Biol. Chem., 280, 10997–11006.

Hertzog, E.D. (2007) Neurons and networks in daily rhythms. Nat. Rev. Neu-

rosci., 8, 790–802.

Hofmann, T., Obukhov, A.G., Schaefer, M., Harteneck, C., Guinderman, T. & Schultz, G. (1999) Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature, 397, 259–263.

Ikeda, M., Sugiyama, T., Wallace, C.S., Gompf, H.S., Yoshikawa, T., Miyawaki, A. & Allen, C.N. (2003) Circadian dynamics of cytosolic and nuclear Ca^{2+} in single suprachiasmatic nucleus neurons. Neuron, 38, 253–263.

Itowi, N., Yamatodani, A., Nogai, K., Nakagawa, H. & Wada, H. (1990) Ef-

fects of histamine and alpha-fluoromethylhistidine injections on circadian phase of free-running rhythms. Physiol. Behav., 47, 549–554.

Itowi, N., Yamatodani, A., Mochizuki, T. & Wada, H. (1991) Effects of intracerebroventricular histamine injection on circadian activity phase
entainment during rapid illumination changes. *Neurosci. Lett.*, **123**, 54–56.

Jafri, M.S., Moore, K.A., Taylor, G.E. & Weinreich, D. (1997) Histamine H1 receptor activation blocks two classes of potassium current, IKrest and IAHP, to excite ferret vagal afferents. *J. Physiol.*, **503**(Pt 3), 533–546.

Johnson, J.W. & Ascher, P. (1987) Glycine potentiates the NMDA response in rat supraoptic neurons. *Chem. Pharmacol. Exp. Ther.*, **314**(2), 253–255.

Kim, B.M., Lee, S.H., Shim, W.S. & Oh, U. (2004) Histamine-induced Ca2+ influx via the PLA2/lipoxygenase/TRPV1 pathway in rat sensory neurons. *Neurosci. Lett.*, **361**, 159–162.

Kim, D.Y., Choi, H.J., Kim, J.S., Kim, Y.S., Jeong, D.U., Shin, H.C., Kim, M.J., Han, H.C., Hong, S.K. & Kim, Y.I. (2005) Voltage-gated calcium channels play crucial roles in the glutamate-induced phase shifts of the rat suprachiasmatic circadian clock. *Eur. J. Neurosci.*, **21**, 1215–1222.

Li, Z. & Hatton, G.I. (1996) Histamine-induced prolonged depolarization in rat supraoptic neurons: G-protein-mediated, Ca2+-independent suppression of K+ leakage conductance. *Neuroscience*, **70**, 145–158.

Lin, J.S., Sergeeva, O.A. & Haas, H.L. (2011) Histamine H3 receptors and sleep-wake regulation. *J. Pharmacol. Exp. Ther.*, **336**, 17–23.

Liou, S.Y., Shibata, S., Yamakawa, K. & Ueki, S. (1983) Inhibitory and excitatory effects of histamine on suprachiasmatic neurons in rat hypothalamic slice preparation. *Neurosci. Lett.*, **41**, 109–113.

Marley, P.D., Thomson, K.A., Jachno, K. & Johnston, M.J. (1991) Histamine-induced increases in cyclic AMP levels in bovine adrenal medulary cells. *Brit. J. Pharmacol.*, **104**, 839–846.

Maruto, T., Nakahara, T., Sakamoto, K., Saito, M., Sugimoto, N., Takuwa, Y. & Ishii, K. (2005) Involvement of the betagamma subunits of G proteins in the cAMP response induced by stimulation of the histamine H1 receptor. *N.-S. Arch. Pharmacol.*, **372**, 153–159.

Mercado, C., Díaz-Muñoz, M., Alamilla, J., Valderama, K., Morales-Tablán, V. & Aguilar-Roblero, R. (2009) Ryanodine-sensitive intracellular Ca2+ channels in rat suprachiasmatic nuclei are required for circadian clock control of behavior. *J. Biol. Rhythm.*, **24**, 203–210.

Meyer, J.L., Hall, A.C. & Harrington, M.E. (1998) Histamine phase shifts the hamster circadian pacemaker via an NMDA dependent mechanism. *J. Biol. Rhythm.*, **13**, 288–295.

Michelsen, K.A., Lozada, A., Kaslin, J., Karlstedt, K., Kukko-Lukjanov, T.K., Holopainen, I., Ohtsu, H. & Punula, P. (2005) Histamine-immunoreactive neurons in the mouse and rat suprachiasmatic nucleus. *Eur. J. Neurosci.*, **22**, 1997–2004.

Moosmang, S., Lenhardt, P., Haider, N., Hofmann, F. & Wegener, J.W. (2005) Mouse models to study L-type calcium channel function. *Pharmacol. Therapeut.*, **106**, 347–355.

Naum, S.S., Farnell, Y.Z., Griffith, W. & Earnest, D.J. (2005) Circadian regulation and function of voltage-dependent calcium channels in the suprachiasmatic nucleus. *J. Neurosci.*, **25**, 9304–9308.

Pfeffer, M., Müller, C.M., Mordel, J., Meissl, H., Ansari, N., Deller, T., Korf, H.W. & von Gall, C. (2009) The mammalian molecular clockwork controls rhythmic expression of its own input pathway components. *J. Neurosci.*, **29**, 6114–6123.

Qu, Y., Baroudi, G., Yue, Y., El-Sherif, N. & Boutjdir, M. (2005) Localization and modulation of [alpha]1D (Cav1.3) L-type Ca channel by protein kinase A. *Am. J. Physiol.-Heart C.*, **288**, H2123–H2130.

Ramadan, O. & Boutjdir, M. (2009) PKA activation regulates L-type Cav1.3 calcium channel in vivo. *Circulation*, **120**, S626–S626.

Reghunandan, V. & Reghunandan, R. (2006) Neurotransmitters of the suprachiasmatic nuclei. *J. Circadian Rhythm.*, **4**, 2.

Scott, G., Piggins, H.D., Semba, K. & Rusak, B. (1998) Actions of histamine in the suprachiasmatic nucleus of the Syrian hamster. *Brain Res.*, **783**, 1–9.

Sheen, Y., Yu, D., Hiel, H., Liao, P., Yue, D.T., Fuchs, P.A. & Soong, T.W. (2006) Alternative splicing of the Cav1.3 channel IQ domain, a molecular switch for Ca2+-dependent inactivation within auditory hair cells. *J. Neurosci.*, **26**, 10690–10699.

Shim, W.S., Tak, M.H., Lee, M.H., Kim, M., Koo, J.Y., Lee, C.H. & Oh, U. (2007) TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. *J. Neurosci.*, **27**, 2331–2337.

Smith, B.N. & Armstrong, W.E. (1996) The ionic dependence of the histamine-induced depolarization of vasopressin neurones in the rat supraoptic nucleus. *J. Physiol.*, **495**(Pt 2), 465–478.

Stehle, J. (1991) Effects of histamine on spontaneous electrical activity of neurons in rat suprachiasmatic nucleus. *Neurosci. Lett.*, **130**, 217–220.

Watanabe, T., Taguchi, Y., Shiosaka, S., Tanaka, J., Kubota, H., Terano, Y., Tohyama, M. & Wada, H. (1984) Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. *Brain Res.*, **295**, 13–25.

Welsh, D.K., Takahashi, J.S. & Kay, S.A. (2010) Suprachiasmatic nucleus: cell autonomy and network properties. *Annu. Rev. Physiol.*, **72**, 551–577.

Xu, W. & Lipscombe, D. (2001) Neuronal Cav1.3alpha(1) L-type calcium channel with dihydropyridines. *J. Neurosci.*, **21**, 9594–9591.

Yoshimatsu, H. (2008) Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm. *Nutrition*, **24**, 827–831.

Zhou, J., Lee, A.W., Devidze, N., Zhang, Q., Kow, L.M. & Paff, D.W. (2007) Histamine-induced excitatory responses in mouse ventromedial hypothalamic neurons: ionic mechanisms and estrogenic regulation. *J. Neurophysiol.*, **98**, 3143–3152.